News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Investment demonstrates confidence in America’s commitment to science and innovation
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Awards highlight Avantor's commitment to the Biopharma industry
Subscribe To Our Newsletter & Stay Updated
